R&D

At Polpharma, we create innovations that ensure the availability and greater safety of our products, greater ease of use of drugs and improvement of patient compliance with therapeutic recommendations, and higher effectiveness of a therapy. We are one of the most innovative companies in Poland – which is confirmed by national rankings.

Three people in laboratory looking at document

We invest significant resources in the development of new products. Our domain is generic drugs, thanks to which we enable access to modern therapies for a wide group of patients. We conduct our own research and development, and we cooperate with universities and research institutes in Poland and abroad. We develop products in new, very advanced areas: ophthalmology, spirometry (asthma) and injectables (long-acting injections for the treatment of schizophrenia).

 

Polpharma invests significant resources in the development of new products and innovative solutions

Our specialisations

We develop a broad range of forms and specialise in difficult-to-make products.

We have three R&D centres located in proximity to three manufacturing sites. See the projects and forms we specialise in:

 

Wide range of Polpharma R&D projects

 

Our specializations – legend

 

R&D Dry Powder Inhalers icon      Orally Inhaled Products: Dry Powder Inhalers (DPI)

Icon tablets   Tablets: Immediate release (IR)  Modified release (SR, XR, DR)  Combinations

Icon capsules   Capsules: Hard gelatin  Soft gelatine (GR softgel)  Twist-off

Icon eye drops    Eye drops: Solutions  Suspensions  Preservative free (ECO) forms

Icon sterile injections and infusions   Sterile injections & infusions: Long Acting Injectables (LAI)

 

FDF DEVELOPMENT EXAMPLES

 

  • ORLISTAT hard capsule the only generic manufacturer in EU
  • PROPOFOL suspension for infusion 〉successful development
  • DISULFIRAM implantation tablets 〉successful development
  • EYE DROPS SOLUTION ECO 〉9 multidose, preservative free (ECO) products successfully developed

Our R & D in numbers

Polpharma is a leader in inventiveness - according to the European Patent Office (EPO), in 2019 Polpharma once again ranked first among all Polish enterprises in terms of the number of patent applications filed (6). More Polish applications to the EPO were received only from the Jagiellonian University (12).

People in laboratory
  • 419 R&D employees, including 72 with a doctorate
  • Polpharma Group R & D centres with strategic partners – 3 in Poland and 2 abroad
  • Spending on research and development in Poland: PLN 301 million in 2017; PLN 205 million in 2018
  • PLN 1,500 million for research and development in 2000-2017
  • Currently, Polpharma Group is conducting 270 development projects
  • Investments in modern factories and laboratories
    – Construction of a new factory for the production of non-sterile forms of medicines in Sieradz, doubling the production capacity in this field and the development of modern inhalation medicines
    – Construction of a competence centre for sterile production (injectable and ophthalmic drugs) in Starogard Gdański
    – Construction of a new factory in Duchnice, which will provide contract production services for global biotechnology companies
    – A pilot line for the production of powders for inhalation and a modern laboratory for analysis in Sieradz

Polpharma B2B

we offer intelligent
solutions
Visit Polpharma B2B
banner

Read also

We invite you to read the next articles on our website
Men yauching digital screen

Digital Solutions

The digital transformation is about people – it is critical to educate, inspire and enable them to engage in this change. It covers digital innovation that will affect the way we execute supporting processes like Digital Workplace, Business Intelligence; internal PR activities, education of employees, collaboration and open communication.
read more
Man and woman working in a laboratory

Active pharmaceutical ingredients (API)

We are the largest Polish manufacturer of active pharmaceutical ingredients (APIs), i.e. active substances for inclusion in finished drug forms.
read more
Photograph of a male and female hand writing in a notebook

For business partners

We are convinced that business partnerships are an important factor in the development of Polpharma Group.
read more

Polpharma on its websites and mobile applications (“Website”) uses cookies and other related technologies (“cookies”). Self-management of cookies is possible by changing the settings in your web browser. If you do not agree to the collection of personal data through cookies, you can change the settings in your web browser or leave the Website.

By using the Website without changing the settings in your web browser, you accept Polpharma’s use of cookies. By accepting the settings in your web browser, you agree to profiling based on the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect the lawfulness of the processing that was carried out on the basis of consent before its withdrawal.

More information can be found in the Cookies Policy.